Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intelligent Prognostic System for Anti-PD-1 in Melanoma
NCT04928365Phase 2Unknown
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Mar 2021
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial in melanoma (2 arms), sponsored by N.N. Blokhin Russian Cancer Research Center. Primary endpoints: Overall Survival at 12 months and Progression-Free Survival at 12 months. Status: unknown.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT04928365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928365.